In a univariate analysis of OS, three variables were significantly associated with OS: resectability at the initiation of treatment for pancreatic cancer (UR-M vs. R, BR, and UR-LA) (HR, 1.82; 95% CI, 1.25–2.66; p = 0.002), HRD-related gene mutation (HR, 0.63; 95% CI, 0.44–0.99; p = 0.049) and baseline Hb levels (HR, 1.58; 95% CI, 1.08–2.30; p = 0.018). Here, GSTM1 is linked to familial pancreatic carcinoma.